Komori
M&A and Subsidiary Changes4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Regarding the Second Request for a Response to the Information List Concerning Large-Scale Purchases of the Company’s Shares or Other Securities by Dalton and Others, Who Are Shareholders of the Company

The company determined that Dalton and others had refused to provide a substantive response to the information list and again requested that they provide the necessary information in Japanese. The company is also concerned that Dalton and others may carry out a large-scale purchase of shares or other securities without complying with the procedures under the response policy.

Worth reading
14Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
30
議決権比率（取得企図）
Wording
Avoiding a definitive answer
How definitive the wording is.

This transaction

ダルトンらによる当社株券等を対象とする大規模買付行為等
Counterpartyダルトン・インベストメンツ・インク (Dalton Investments, Inc.), ニッポン・アクティブ・バリュー・ファンド (NIPPON ACTIVE VALUE FUND PLC), NAVF Select LLC, ダルトン・インベストメンツ・エルエルシー (Dalton Investments LLC), ダルトン・アドバイザリー株式会社, Rosenwald Capital Management, Inc., ライジング・サン・マネジメント (Rising Sun Management Ltd.), Hikari Acquisition, Michael 1925, JMBO Fund Limited
Disclosing companyASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd.Subject of this transaction
This transaction
ItemDetails
Transaction nameダルトンらによる当社株券等を対象とする大規模買付行為等
Counterparty nameダルトン・インベストメンツ・インク (Dalton Investments, Inc.), ニッポン・アクティブ・バリュー・ファンド (NIPPON ACTIVE VALUE FUND PLC), NAVF Select LLC, ダルトン・インベストメンツ・エルエルシー (Dalton Investments LLC), ダルトン・アドバイザリー株式会社, Rosenwald Capital Management, Inc., ライジング・サン・マネジメント (Rising Sun Management Ltd.), Hikari Acquisition, Michael 1925, JMBO Fund Limited
Name of the Subject CompanyASKA Pharmaceutical Holdings Co.,Ltd.
Items this document does not state (29)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceDate of board resolutionContract DateExecution Date / Effective DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

株主および取締役会が大規模買付行為等について適切に判断するために必要な情報を得ること、ならびに情報の正確性を担保することが理由とされている。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Second Request for a Response to the Information List Concerning Large-Scale Purchases of the Company’s Shares or Other Securities by Dalton and Others, Who Are Shareholders of the Company | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori